Global 3D Bioprinting Market Overview:
3D Bioprinting is an embryonic technology which has the potential to transform the medical field with its capacity to bio fabricate living tissues and organs using a patient's own cells in combination with different biomaterials. Although this disruptive technology is still in its infancy researchers, innovators and early adopters are improving the performance of the technology stepwise as it grows. As a result, the 3D bioprinting market overview report is growing pervasively.
Acknowledging the kind of traction gained by this market, Market Research Future (MRFR) in its recently published a study report asserts that the global 3D bioprinting market is projected to accrue voluminously by 2030 registering a phenomenal CAGR of 15.4% during the review period (2023 to 2030). Currently, 3D bioprinting is used to print tissues and organs to help research drugs and pills.
Currently, 3D bioprinting is majorly involved in the creation of simple tissue structures in lab settings, but is estimated to be risen up to involve the creation of complete organs for transplants. This technology is expected to be used for swifter and more accurate drug testing, as potential drug compounds could be tested on bio-printed tissue before human trials begun.
Global 3D Bioprinting Market - Segments:
The MRFR analysis is segmented into five key dynamics for the convenience of understanding;
By Techniques : Electron Beam Melting, The Laser Beam Melting (photo polymerization, stereo lithography, two-photon polymerization, and others.) and Droplet Disposition (inkjet printing, fused disposition methods, multi-phase jet solidification, and others.) among others.
By Applications : Clinical (tissue transplantation, bone grafts, vascular grafts, wound care, and others), and Research (regenerative medicine, personalized healthcare, 3D cell culture, and others) among others.
By Materials : Cells, extracellular matrices, fibrinogen, alginate and Hydrogels among others.
By End Users : Biotechnology Companies, and Academic Institutes among others.
By Regions : North America, Europe, APAC and the Rest-of-the-World.
Global 3D Bioprinting Market - Regional Analysis
The North America market dominates the global 3D Bioprinting market owing to the increasing healthcare expenditure followed by Europe and the Asia Pacific. North America market for 3D Bioprinting is expected to continue with its dominance in the years to come owing to the favorable government regulations coupled with a well-developed healthcare sector and huge patient population for organ transplantation. Furthermore, the growing biotech sector along with the presence of global players like Organovo Holdings, Inc. and Stratasys Ltd. boosts the market growth.
The Europe region accounts for the second-largest 3D Bioprinting market share attributing to the increased research development activities in the field backed by the government support and funds. The market is expected to grow due to the high per capita healthcare expenditures along with the presence of the developed economies like Germany, the UK and France within the region.
Whereas attributing to the huge population and the burgeoning medical treatment market in the region, Asia-Pacific market is emerging as the fastest growing market for 3D Bioprinting. Growing markets of India, China, and Brazil backed by the increasing consumers’ awareness improved lifestyle provide impetus to the market growth. Besides, the improved economy in the region presages the potential this market holds to grow further, creating the opportunities in the 3D Bioprinting market during the forecast period.
On the other hand, the Middle East Africa market witnesses impedimental growth due to the unmet medical needs aroused due to the unavailability of funds, limited medical facilities and the poor political conditions in Africa.
Global 3D Bioprinting Market - Competitive Analysis
With a good number of key players to adorn the global market of 3D bioprinting appears to be a fairly stable industry as far as eyes can see. Innovation, Collaboration, mergers acquisitions, and brand reinforcement remain the key trends for leading players in the market. However; these market players appear to be reluctant to collaborate as engineering firms and suppliers may be reluctant to provide CAD drawings/input to clients, as they risk losing IP.
One of the prominent players, Organovo of USA; which also happens to be the first official 3D bioprinting company, found their niche market in providing pharmaceutical companies with human tissue on demand that can be used for drug screening applications. The cosmetic giant L’Oreal is collaborating with Organovo for toxicity testing. Aspect Biosystems that is developing printed tissue for drug testing.
The fervent players leading the global 3D bio-printing market include Cellink AB (Sweden), Organovo Holdings, Inc. (US), Bio3D Technologies (Singapore), Stratasys Ltd. (US), Aspect Biosystems Ltd. (Canada), Fathom (US), Materialise (US), Envisiontec, Inc. (Germany), Allevi (US), Nano3D Biosciences, Inc. (US), 3Dynamic Systems Ltd. (UK), Cyfuse Biomedical K.K. (Tokyo), REGENHU (Switzerland), and Poietis (France).
Industry/ Innovation /Related News:
August 23, 2018 – Researchers at Brigham and Women’s Hospital (US) published their study for the 3D bioprint tubular structures they developed. These new structures better mimic vessels and ducts in human body. The 3D bioprinting technique allows fine-tuning of the printed tissues' properties, such as number of layers and ability to transport nutrients.
These more complex tissues offer potentially viable replacements for damaged tissue. The team plans to continue preclinical studies to optimize the bio-ink composition and 3-D-printing parameters before testing for safety and effectiveness. They are currently optimizing the parameters and biomaterial even further to create tubular structures with enough mechanical stability to sustain themselves in the body.
August 10, 2018 – Allevi (US), 3D bio-printer manufacturer and Made in Space (US), a company with two 3D printers aboard the International Space Station (ISS), represents the first step toward those scenes of sci-fi medicines, have formed a partnership to send 3D bioprinter to the space station. The two companies ensure that the ZeroG bio extruder, developed by Allevi which is capable of printing biomaterials in microgravity, slots easily into a Made in Space printer to allow astronauts to plug-and-play.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team has the supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071